Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
复制标题
通过与皮下干扰素 - 阿尔法和动脉内5-氟尿嘧啶联合治疗，用主要门静脉血栓形成治疗肝细胞癌癌； 1型干扰素受体表达的作用。
DOI：
10.1038/sj.bjc.6602742
复制
发表时间：
2005-09-05
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
我们先前报道了干扰素（IFN）-α/5-氟尿嘧啶（FU）联合治疗晚期肝细胞癌（HCC）伴主要门静脉分支癌栓的有益效果。本报告描述了较长时间随访的结果，纳入的患者数量是原始报告的两倍以上，并评价了IFN-α/2型干扰素受体（IFNAR 2）表达对联合治疗应答的作用。研究对象为55例晚期HCC和门静脉主要分支（Vp 3或4）肿瘤血栓患者。IFN-α/5-FU治疗2个疗程以上，无严重并发症。在55例患者中，24例（43.6%）显示客观缓解（8例（14.5%）显示完全缓解，16例（29.1%）显示部分缓解），4例（7.3%）显示无缓解，27例（49.1%）显示疾病进展。免疫组化结果显示，13例患者中有9例（69.2%）检测到IFNAR 2表达。IFNAR 2阳性和阴性患者的进展生存时间（P=0.0002）和总生存时间（P<0.0001）差异有统计学意义。在单因素分析中，IFNAR 2表达与IFN-α/5-FU联合治疗的应答显著相关（P=0.0070）。IFN-α/5-FU联合治疗是一种有希望的治疗晚期肝癌伴门静脉癌栓的方法，并且可能显著依赖于IFNAR 2的表达。
We previously reported the beneficial effects of combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches. This report describes the results of longer follow-up and includes more than double the number of patients relative to the original report, and evaluates the role of IFN-α/type 2 interferon receptor (IFNAR2) expression on the response to the combination therapy. The study subjects were 55 patients with advanced HCC and tumour thrombi in the major branches of the portal vein (Vp3 or 4). They were treated with at least two courses of IFN-α/5-FU without major complication. In the 55 patients, 24 (43.6%) showed objective response (eight (14.5%) showed complete response, 16 (29.1%) partial response), four (7.3%) showed no response, and 27 (49.1%) showed progressive disease. Immunohistochemically, IFNAR2 expression was detected in nine out of 13 (69.2%) patients. There was significant difference in the time-to-progression survival (P=0.0002) and the overall survival (P<0.0001) between IFNAR2-positive and -negative cases. There was a significant correlation between IFNAR2 expression and response to IFN-α/5-FU combination therapy in univariate analysis (P=0.0070). IFN-α/5-FU combination therapy is a promising modality for advanced HCC with tumour thrombi in the major portal branches and could significantly depend on IFNAR2 expression.
登录
查看更多内容
影响因子：
4.2
作者：
Fujiwara, D;Hino, K;Okita, K
通讯作者：
Okita, K
影响因子：
11.5
作者：
Kurokawa, Y;Matoba, R;Monden, M
通讯作者：
Monden, M
影响因子：
10.3
作者：
GUADAGNI, F;SCHLOM, J;GREINER, JW
通讯作者：
GREINER, JW
DOI：
10.1111/j.1440-1746.1994.tb01207.x
发表时间：
1994-01-01
影响因子：
4.1
作者：
CHEN, SC;HSIEH, MY;CHANG, WY
通讯作者：
CHANG, WY
影响因子：
6.4
作者：
ORTALDO, JR;MANTOVANI, A;HERBERMAN, RB
通讯作者：
HERBERMAN, RB